TABLE 1.

Ex vivo analysis of peripheral blood leukocyte subsets and activation status in the patient with combined neurotropic and viscerotropic disease following 17D YF vaccination

Cell typeCell phenotypeValuea
RVPatient
MonocytesCD14+ CD16+ DR++/CD14+ CD16+71.0 ± 14.854.0
CD16 (MFI) in CD14+101.0 ± 48.0↓20.0*
CD32 (MFI) in CD14+215.0 ± 47.0↓39.0**
CD64 (MFI) in CD14+91.0 ± 25.0↓28.0**
NK cellsCD3 CD16−/+ CD56−/+15.0 ± 7.512.0
    CD3 CD16+ CD56/NK cells11.0 ± 7.17.0
    CD3 CD16+ CD56+/NK cells78.0 ± 9.693.0
NK T cellsCD3+ CD16+/− CD56+/−/CD3+12.0 ± 3.9↑ 40.0**
T cellsCD3+67.0 ± 7.266.0
    CD4+39.0 ± 6.238.0
        CD18 (MFI) in CD4+40.0 ± 9.9↓9.0**
        CD4+ CD54+/CD4+4.0 ± 2.2↑ 24.0**
        CD4+CD62L+/CD4+68.0 ± 8.9↓23.0**
        CD4+CD69+/CD4+3.0 ± 1.8↑ 10.0**
        CD4+CD38+/CD4+41.0 ± 9.8↓10.0**
        CD4+CD28+/CD4+96.0 ± 1.895.0
        CD4+HLA-DR+/CD4+4.0 ± 2.0↑ 11.0**
        CD4+CD25High1.9 ± 0.9↓0.8*
        IL-10R (MFI) in CD4+10.7 ± 5.5↓3.0*
    CD8+28.0 ± 5.828.0
        CD18 (MFI) in CD8+68.0 ± 20.4↓10.0**
        CD8+ CD54+/CD8+6.0 ± 4.0↑ 18.0**
        CD8+ CD62L+/CD8+48.0 ± 6.4↓16.0**
        CD8+ CD69+/CD8+11.0 ± 2.810.0
        CD8+ CD38+/CD8+54.0 ± 21.264.0
        CD8+ HLA-DR+/CD8+5.0 ± 2.46.0
        CD8+ CD28+/CD8+59.0 ± 12.140.0
        IL-10R (MFI) in CD8+17.0 ± 6.611.0
B cellsCD19+13.0 ± 4.717.0
    CD19+ CD5+/CD19+24.0 ± 5.522.0
    CD19+ CD5/CD19+75.0 ± 8.278.0
    CD19+ CD23+/CD19+49.0 ± 15.353.0
    CD19+ CD69+/CD19+12.0 ± 3.6↑ 54.0**
    CD32 (MFI) in CD19+160.0 ± 32.0↓11.0**
  • a RV, RVs for peripheral blood leukocyte subset frequencies observed 15 days after 17DD vaccination in the absence of adverse reactions (n = 10); Patient, peripheral blood leukocyte subset frequencies observed in the patient with combined neurotropic and viscerotropic disease following 17D YF vaccination. The results are expressed as the mean percentage ± SD of positive cells unless MFI is indicated, in which case the results are expressed as the mean MFI ± SD for the expression of a given cell surface marker within gated lymphocytes. *, statistical significance was considered when the values for the patient were outside of the RV range (mean ± 2 SDs); **, additional statistical significance was considered when the values for the patient were outside the range of 0.5 to 2.0 times the mean RVs. ↑ and ↓, increase and decrease in the values, respectively, in comparison to the RVs.